5 papers in the library · 27 citations · publishing 2024-2026
Transl Psychiatry May 29, 2026 Justyna K. Hinchcliffe, Katie Kamenish, Julia M. Bartlett et al.
Differences in how NMDA antagonists modulate negative affective biases in male rats may serve as a predictor of clinical efficacy in major depressive disorder.
bioRxiv (Cold Spring Harbor Laboratory) March 4, 2026 Matthew D. B. Claydon, Justyna K. Hinchcliffe, Julia M. Bartlett et al.
Abstract Psilocybin, a serotonergic psychedelic, can produce rapid and enduring antidepressant effects in patients with major depressive disorder (MDD)[1, 2], yet the neural mechanisms underlying these effects remain unclear. Negative affective biases are an important neuropsychological mechanism central to the development and perpetuation of MDD[3]. Using a translational rodent model, we...
bioRxiv (Cold Spring Harbor Laboratory) January 15, 2026 Justyna K. Hinchcliffe, Christopher W. Thomas, Gary Gilmour et al.
Abstract The serotonergic psychedelic, psilocybin, shows potential for rapid and sustained antidepressant effects but the underlying mechanisms remain unknown. Using a chronic interferon-alpha–induced rat model of depression, we show acute psilocybin (0.3 mg/kg) reverses impaired reward-induced biases within 24hrs, with effects enduring for at least 7 days. This suggests psilocybin can restore...
bioRxiv (Cold Spring Harbor Laboratory) November 1, 2025 Dasha Anderson, Justyna K. Hinchcliffe, Megan N. Jackson et al. 1 citation preprint
Abstract Background Behavioural studies in animal models represent a critical component of psychiatric drug development. Positive results in animal studies have identified novel therapeutic targets for major depressive disorder (MDD) but efficacy in humans has largely not been borne out in clinical trials. A possible reason for this failed translation is inappropriate dose selection and the...
Science Translational Medicine January 10, 2024 Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu et al. 26 citations
How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment....